**Executive Summary**
This document outlines the amendments to the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, notified on October 1, 2025, aimed at enhancing its implementation and effectiveness. The scheme comprises two components: establishing centers of excellence at NIPERs and promoting research and innovation in the Pharma MedTech sector. The document specifies financial assistance details for various projects under the scheme.
**Key Points / Main Content**
* **Scheme Overview:**
* The PRIP scheme was amended on October 1, 2025.
* The amended scheme intends to facilitate smooth implementation and effective benefit-sharing.
* **Components of the PRIP Scheme:**
* **Component A:** Strengthening research infrastructure by establishing centers of excellence at National Institutes of Pharmaceutical Education and Research (NIPERs).
* **Component B:** Promotion of research and development in the Pharma MedTech sector, supporting development of products, technologies, or expeditious validation of research and development for market launch and large-scale commercialisation. Priority areas include new medicines, complex generics and biosimilars, and novel medical devices.
* **NIPER Centers of Excellence:**
* Seven centers of excellence have been established under Component A, one at each of the seven NIPERs.
* The locations and approved outlays are as follows:
* NIPER, Mohali (Punjab): ₹100 crore
* NIPER, Ahmedabad (Gujarat): ₹110 crore
* NIPER, Guwahati (Assam): ₹100 crore
* NIPER, Kolkata (West Bengal): ₹100 crore
* NIPER, Raebareli (Uttar Pradesh): ₹100 crore
* NIPER, Hajipur (Bihar): ₹99.99 crore
* NIPER, Hyderabad (Telangana): ₹90 crore
* **Financial Assistance Under Component B:**
* **Early Stage Projects:** MSMEs and startups may apply for projects costing up to ₹9 crore with assistance of up to ₹5 crore.
* **Later Stage Projects:** Industry projects, MSMEs, and startups can apply for projects costing up to ₹285 crore with assistance up to ₹100 crore.
* **Scale of Assistance:**
* **Early Stage Projects:** 100% of costs up to ₹1 crore; 50% of additional cost beyond ₹1 crore, up to ₹5 crore max.
* **Later Stage Projects:** 35% of project cost (50% for Strategic Priority Innovation areas) up to ₹100 crore max.
* Applications are invited from the pharmaceutical and MedTech industry and startups for research and innovation projects.
* Startups and industries applying for financial assistance under component B do not need to declare the State where they are registered.
* **Strategic Priority Innovation Areas:**
* Projects addressing India's public health concerns, but with relatively lower market potential.
* Financial assistance for Later Stage Projects in these areas may be up to 50% of the approved total project cost, to a maximum of ₹100 crore.
* **Institution Strengthening:**
* Under component A, institutional strengthening of research infrastructure has been undertaken through the setting up of centres of excellence at the seven National Institutes of Pharmaceutical Education and Research.
* Industry and startups are encouraged to collaborate with Government academic and research institutions to develop, translate and commercialise intellectual property under Component B.
* **Related Schemes:**
* The Department of Pharmaceuticals has launched several schemes, including the Production Linked Incentive (PLI) Scheme for Pharmaceuticals and the Scheme for Promotion of Bulk Drug Parks, to promote the Pharma-MedTech industry and generate employment.
**Impact Analysis**
**NIPERs**
* **Impact:** Will benefit from setting up centers of excellence to strengthen research infrastructure and promote advanced research in pharmaceutical sciences and medical technologies.
* **Action Required:** Utilize approved outlays to establish and operate centers of excellence, aligning research with identified priority areas.
**Pharma and MedTech Industry and Startups**
* **Impact:** Eligible to receive financial assistance for research and innovation projects under Component B, potentially leading to the development of new medicines, generics, biosimilars, and medical devices.
* **Action Required:** Apply for financial assistance for eligible projects, either as Early Stage or Later Stage Projects, and collaborate with academic and research institutions as per scheme guidelines.
**Department of Pharmaceuticals**
* **Impact:** Responsible for implementing the amended PRIP scheme, which aims to facilitate smooth implementation, bring clarity in governance and make benefit-sharing mechanisms more effective.
* **Action Required:** Oversee the implementation of Component A and Component B, ensure adherence to scheme guidelines, and monitor the progress of funded projects.
**Public Health Sector**
* **Impact:** Expected to benefit from the scheme through the development of new medicines, medical devices, and technologies that address priority public health concerns.
* **Action Required:** N/A
Key Entities Referenced
Promotion of Research and Innovation in PRIP Scheme: A scheme to promote research and innovation in the Pharma MedTech sector, focusing on strengthening research infrastructure and providing financial assistance.
Department of Pharmaceuticals: The government department responsible for launching and overseeing the PRIP scheme and other related initiatives in the pharmaceutical sector.
National Institute of Pharmaceutical Education and Research (NIPERs): Institutes of national importance that are centers of excellence for strengthening research infrastructure under Component A of the PRIP scheme.
Production Linked Incentive (PLI) Scheme for Pharmaceuticals: A scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
Promotion of Research and Innovation in PRIP
Scheme
प्रव तथ: 12 DEC 2025 4:22PM by PIB Delhi
Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme was amended and the
amended scheme was notified on 1.10.2025. The recent amendments were carried out to facilitate smooth
implementation, to bring greater clarity in governance and to make benefit-sharing mechanisms more
effective.
Key features of the scheme as amended are as under:
(i) It has two components, namely, Component A: Strengthening the research
infrastructure through setting up of centres of excellence at National Institute of
Pharmaceutical Education and Research (NIPERs) and Component B: Promotion of
Research and Innovation in Pharma MedTech sector.
(ii) Component A is for setting up of centres of excellence at NIPERs.
(iii) Component B is for providing financial assistance to support research and development
(R&D) for development of products and technologies (outputs) or expeditious validation of
R&D outputs for market launch and large-scale commercialisation in three priority areas,
namely new medicines, complex generics and biosimilars, and novel medical devices.
Under component A, a total of seven centres of excellence have been set up, one at each of the seven
NIPERs established at the following places:
(i) NIPER, Mohali, in the State of Punjab, with an approved outlay of ₹100 crore;
(ii) NIPER, Ahmedabad, in the State of Gujarat, with an approved outlay of ₹110 crore;
(iii) NIPER, Guwahati, in the State of Assam, with an approved outlay of ₹100 crore;
(iv) NIPER, Kolkata, in the State of West Bengal, with an approved outlay of ₹100 crore;
(v) NIPER, Raebareli, in the State of Uttar Pradesh, with an approved outlay of ₹100
crore;
(vi) NIPER, Hajipur, in the State of Bihar, with an approved outlay of ₹99.99 crore; and
(vii) NIPER, Hyderabad, in the State of Telangana, with an approved outlay of ₹90 crore.
Under component B of the scheme, for Early Stage Projects, MSMEs and startups may apply for projects
costing up to ₹9 crore for assistance of up to ₹5 crore. For Later Stage Projects, projects of industry,
MSMEs and startups costing up to ₹285 crore may apply for assistance up to ₹100 crore. The scale of
financial assistance for Early Stage Projects is 100% for cost up to ₹1 crore and 50% of additional cost
beyond ₹1 crore, subject to a maximum up to ₹5 crore. The scale for financial assistance for Later StageProjects is 35% of the project cost (50% in case of projects in Strategic Priority Innovation areas), subject
to a maximum of ₹100 crore. Under this component, the Department of Pharmaceuticals has invited
applications for research and innovation projects from pharmaceutical and MedTech industry and startups.
The application process for financial assistance under component B of the scheme does not require
startups and industries to declare the State where they are registered.
The criteria adopted for inclusion of projects in Strategic Priority Innovation areas is that they address
areas of India’s public health concern for which market potential is relatively lower. For Later Stage
Projects in these areas, financial assistance may be to the extent of 50% of the approved total project cost,
as against 35% for projects in other areas, subject to a maximum of ₹100 crore.
The arrangements under the scheme to institutionally promote the national pharma-MedTech innovation
ecosystem include the following:
i. Under component A, institutional strengthening of research infrastructure has been undertaken
through the setting up of centres of excellence at the seven National Institutes of Pharmaceutical
Education and Research, which are institutes of national importance for imparting postgraduate and
doctoral education and conduct high-end research in various specialisations in pharmaceutical
sciences and medical technologies. These centres are in the specialisations of anti-viral and anti-
bacterial drug discovery and development, medical devices, bulk drugs, flow chemistry and
continuous manufacturing, novel drug delivery system, phyto-pharmaceuticals and biological
therapeutics, with a view to help in building specific research capacities in the identified priority
areas, tapping industry-academia linkage. These are aimed at strengthening the research
infrastructure in the pharma-MedTech sector by providing advanced facilities to conduct research
and help in nurturing talent pool by promoting industry-academia linkage.
ii. Under component B, industry and startups are encouraged under the scheme to collaborate flexibly
with reputed Government academic and research institutions specified in the Scheme guidelines to
develop, translate and commercialise institutional intellectual property and to augment institutional
research capacities in India.
The Department of Pharmaceuticals has launched the Production Linked Incentive (PLI) Scheme for
Pharmaceuticals, the PLI scheme for promotion of domestic manufacturing of critical Key Starting
Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India
(commonly referred to as PLI Scheme for Bulk Drugs), the Strengthening of Pharmaceuticals Industry
scheme, PRIP scheme and the Scheme for Promotion of Bulk Drug Parks to promote pharma-MedTech
investment and research across regions, including in clusters in industrially underdeveloped regions, with
a view to promote the industry and generate skilled and unskilled employment. Under the PLI Schemes
for Pharmaceuticals and Bulk Drugs and the Strengthening of Pharmaceuticals Industry scheme, projects
spread across 21 States and Union territories at over 540 manufacturing locations, including 18 projects
located in districts identified as aspirational districts by NITI Aayog, have been approved.
This information was given by Union Minister of State in the Ministry of Chemicals and Fertilizers, Smt.
Anupriya Patel, in a written reply in the Lok Sabha today.
******
PC/PM
(रलीज़ आईडी: 2203001) आगंतुक पटल : 424
इस वज्ञ को इन भाषाओ ंम पढ़: ही